10 Periods of normalcy can last weeks, months, or years between cycles, with abnormal periods also varying significantly.
D iagnosing
Cushing's syndrome (CS) is challenging, and there are several potential pitfalls. A subset of patients exhibit cyclic or periodic hypersecretion of cortisol with intermittent periods of normal secretion. A variety of presentations exist, including regular cyclic hormone secretion with or without variations in clinical symptoms and irregular cycles of cortisol secretion with or without corresponding changes in phenotypic expres sion. 10 Periods of normalcy can last weeks, months, or years between cycles, with abnormal periods also varying significantly. 1 Making the correct diagnosis can be ham pered by these normal periods, and results of testing can lead to errors in the differential diagnosis. Here, we pre sent an interesting case of cyclic CS in a patient who was ultimately found to have Cushing's disease from an ad renocorticotropic hormone (ACTH)-producing pituitary adenoma.
Case Report
A 63yearold woman with a medical history of resis tant hypertension presented with complaints of intermittent weight gain, bruising, progressive fatigue, and emotional lability. On examination, she was noted to have classic cushingoid features with moon facies, plethora, central obesity, upper arm and leg muscle atrophy, and bruises. Her blood pressure was 110/74 mm Hg, her weight was 180 lbs, her height was 61 inches, and her body mass index was 34 kg/m 2 . The neurological examination revealed that she had an inability to rise from a squatting position.
Investigations
Biochemistry. Two 24hour urinary free cortisol (UFC) tests were completed and revealed elevated levels of 225 and 175 mg/24 hours (reference range < 50 mg/24 hours). Her plasma ACTH level was 26 pg/ml (reference range 5-27 pg/ml). A 1mg overnight dexamethasone suppression test revealed a morning serum cortisol con centration of 22 mg/dl (reference range < 1.8 mg/dl), and a lowdose 2day (2 mg/day) dexamethasone suppression test revealed 24hour UFC levels that were suppressed from 48 to 38 mg/24 hours (reference range > 50% sup pression). A highdose (8mg) overnight dexamethasone suppression test revealed a pretreatment serum cortisol level of 21 mg/dl, which was suppressed to 5.4 mg/dl after dexamethasone administration. Her insulinlike growth factor-1 level was 76 ng/ml, her prolactin level was 8.3 ng/ml, her free thyroxine level was 1.3 ng/dl, her thyroid stimulating hormone level was 0.7 mIU/L, her luteinizing hormone level was < 0.2 IU, and her folliclestimulating hormone level was < 0.7 IU (inappropriately suppressed for a postmenopausal woman). The results of an oral glu cosetolerance test were consistent with impaired glucose tolerance.
Imaging. Pituitary MRI was suggestive of a small cen tral hypointense lesion. A dualenergy xray absorptiom etry scan confirmed osteoporosis.
Follow-Up
With a diagnosis of ACTHdependent CS, the patient underwent the initial inferior petrosal sinus sampling (IPSS) (Table 1), 7 months after her presentation and ini tial workup from her referring endocrinologist. The IPSS results revealed a < 2:1 centraltoperipheral gradient at baseline, with a < 3:1 gradient of centraltoperipheral ACTH in the petrosal sinus samples after corticotropin releasing hormone (CRH) administration. An isolated centraltoperipheral gradient was seen (> 3:1) in samples obtained from the jugular vein, but it was believed to be inconsistent with petrosal samples and nondiagnostic. Without a clear centraltoperipheral gradient between the petrosal samples and the peripheral measurements, the IPSS results were considered indeterminate and not supportive of a diagnosis of central ACTHdependent Cushing's disease.
No additional samples for 24hour UFC testing had been collected since the time of the patient's initial pre sentation. At that time, she reported that her symptoms as sociated with CS had resolved in the weeks leading up to the IPSS procedure. Her facial plethora and weakness had improved dramatically. It was decided to reevaluate the patient with further testing before proceeding with further investigation of the source of the ACTH. Serial samples for 24hour UFC measurements ( Fig. 1) were then col lected for 11 months to document cortisol hypersecretion. A second IPSS procedure was scheduled during a cortisol hypersecretory phase ( Table 2 ). The second IPSS proce dure was diagnostic of a central source for ACTH, which supported a diagnosis of Cushing's disease. The peaks and troughs revealed by serial measurements of 24hour UFC levels suggested a diagnosis of cyclic Cushing's disease.
Treatment and Posttreatment Course
The patient underwent transsphenoidal surgery, with removal of a microadenoma and the inferior central por tion of the pituitary gland. Pathology confirmed a sparsely granulated corticotroph adenoma (Ki 67 < 1%) that was p53 negative. Postoperatively, her serum cortisol con centration reached a nadir of 1.1 mg/dl on Postoperative Day 2, falling from 9.6 mg/dl on Postoperative Day 1. She was discharged from the hospital after being placed on a hydrocortisone replacement regimen and reported symp toms of steroid withdrawal in the perioperative time pe riod. She lost 8 lbs, complained of joint aches, and expe rienced resolution of her hypertension without taking her antihypertensive medication. Her recovery was otherwise uneventful, and she returned to her referring endocrinolo gist for longterm followup.
discussion
This case clearly documents several peaks and troughs of cortisol secretion as measured by frequent 24hour sam ple collections for UFC testing. The results of IPSS per formed during a trough phase were more consistent with a peripheral source of ACTH, given the lack of gradient between the petrosal and peripheral samples at baseline and after CRH administration, but were indeterminate at the time and required further investigation. Although it was not recognized at the time, one potential explanation for the results was that the patient had cyclic CS and was studied during a trough phase. Another potential source for error was improper cannulation of the petrosal sinuses leading to the errant measurement of ACTH levels. Both of these situations necessitate repeat performance of IPSS. The correct diagnosis was made by restudying the patient after demonstrating periodicity of cortisol secretion and ensuring that the IPSS was performed during a phase of active cortisol secretion.
CS is an important clinical entity with several delete rious effects on health, including dyslipidemia, impaired glucose tolerance, hypertension, bone loss, proximal mus cle wasting, weight gain, and mood disturbances. In clas sic CS, cortisol levels are elevated without diurnal varia tion, and normal feedback inhibition of cortisol secretion is diminished. Cyclic CS is a rare subtype of CS in which periods of biochemical and/or clinical hypercortisolism alternate with periods of eucortisolism. A variety of subcategories have been described. 10 Cyclic patterns of biochemical hy percortisolism may be regular or irregular and have vari able or constant clinical manifestations. Cycle durations have also been noted to vary between weeks and years. 8 Although it is rarely diagnosed, cyclic CS may in fact be more frequent than commonly thought. Indeed, a ret rospective study of 201 patients with CS found cyclic variability in 30 (15%) of them.
1 Difficulties in diagnosis underlie the underreporting of this phenomenon. As dem onstrated in our case report, capturing a period of cortisol excess and confirming the diagnosis during this time pe riod may be challenging. A generally accepted diagnos tic criterion for cyclic CS is the recognition of 2 cycles (3 peaks and 2 troughs) of cortisol production, 3 although others consider 1 complete cycle (2 peaks and 1 trough) sufficient for making the diagnosis. Any etiology of CS can produce cyclic patterns of hy percortisolism. In a review of 65 published cases of cyclic CS, 54% were caused by ACTHproducing pituitary ad enomas, 26% were caused by ectopic ACTH production, and 11% were a result of ACTHindependent causes. 8 The pathophysiology has yet to be defined clearly, although some theories have been proposed. A histological find ing of necrosis within tumors led some investigators to propose that episodic hemorrhage and necrosis of corti solproducing cells causes a cyclical release of cortisol, 7 although others have identified cases of cyclical CS with out necrosis in the tumor specimen. 2 Another theory pos tulates that tumor calcifications lead to infarction with subsequent eucortisolemia; 4 however, this theory does not explain the periodicity. A third theory involves potential hypothalamic causes as mediators of pulsatile ACTH hy persecretion. Neurotransmitters thought to be involved in clude CRH, noradrenaline, dopamine, acetylcholine, and gaminobutyric acid. 8 Diagnosis of typical CS is known to be challenging be cause no single test has ideal diagnostic accuracy, which results in the need for multiple tests to confirm a diagno sis. According to Endocrine Society practice guidelines, screening tests include 24hour UFC measurement, mid night salivary cortisol measurement, and the 1mg dexa methasone suppression test, with a note that urinary and salivary levels should be measured at least twice given the variability in results. 9 A diagnosis of cyclical CS is com plicated further by the relapse and remission of biochemi cal and clinical findings and the need for close monitoring and coordination of confirmatory tests. Furthermore, an increased duration of testing is required given the vary ing periods of remission, which are known to last up to 5 years. This poses a major obstacle in the ability to admin ister appropriate management in a timely fashion.
Novel diagnostic methods are being explored to cir cumvent this pitfall. Hair cortisol levels are known to be significantly elevated in patients with CS over those in the general population (sensitivity 86%, specificity 98%). 6 The advantage of using hair cortisol levels is that they can pro vide data over the previous several months in one analyti cal setting. In one study, hair samples were obtained from one lock of hair each from healthy controls, patients with CS, and patients with cyclic CS. 6 Cortisol measurements at 1cm intervals correspond to monthly time frames. In patients with cyclic CS, hair cortisol-level fluctuations were found to correlate with the clinical course of CS. 6 In another report, a desmopressin acetate (DDAVP) stimula tion test was used for a case in which biochemical evi dence was not confirmed, resulting in a 2-year delay of the eventual discovery of an ACTHproducing pituitary adenoma. 5 Thus, both the analysis of hair cortisol and the DDAVP stimulation test may improve on the diagnostic approach by significantly shortening the time to diagnosis and enabling more timely management.
As with classic CS, the treatment of cyclical CS gener ally involves surgical removal of the tumor or, for patients who are not candidates for surgery, medical management. However, posttreatment management poses a unique set of challenges in these patients. Patients with cyclic CS caused by pituitary disease have a significantly higher recurrence rate postoperatively (63%) and lower cure rates (25%) than those of patients with noncyclical CS (approximately 80% cure rate). 8 Moreover, postoperative management is com plicated by the fact that normal cortisol levels in these pa tients may not be indicative of cure but instead correspond to a period of quiescence. In this situation, there is a need to closely monitor for longer periods of time, and perhaps more frequently than usual, to ensure the capture of a re lapse if it occurs. It was fortunate that, in our case, the postoperative symptoms of cortisol withdrawal and the need for steroid replacement were strongly indicative of remission in this patient.
We report here a case that clearly documents multiple peaks and troughs of cortisol secretion, as measured by frequent sampling of 24hour UFC levels. The IPSS per formed during a trough phase provided misleading results because of the lack of gradient at baseline and after CRH administration. The correct diagnosis was made by re peating the IPSS and ensuring that it was performed dur ing an active phase of cortisol secretion. It is important to recognize cyclic CS as a clinical entity and to note that its prevalence may be higher than currently believed given the challenges in establishing a diagnosis. A diagnosis of cyclic CS is made by showing peaks and troughs of cortisol secretion either by frequent measurement of cor tisol levels in urine or saliva or perhaps by using novel techniques such as the analysis of hair cortisol levels or DDAVP stimulation testing. As illustrated by this case, the timing of IPSS (i.e., during a period of quiescence) may lead to an incorrect diagnosis and further delay appropri ate management. It is important that testing for the differ ential diagnosis be done only during periods of biochemi cal or clinical hypercortisolism. Management of these patients is complicated by high recurrence rates and low cure rates, which necessitate the need for continued closer monitoring for longer durations of time than for patients with noncyclic CS.
